Trial Profile
A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Gemcitabine (Primary)
- Indications Glandular and epithelial neoplasms; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 08 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 31 Jul 2008 The expected completion date for this trial is now 1 Aug 2009 according to ClinicalTrials.gov.
- 23 Sep 2007 Results presented at ECCO 2007.